• Our Story
  • B. adolescentis
  • iVS-1
  • Discovery Platforms
  • Science
  • Contact
  • Media
  • References
Contact

Synbiotic Health develops new probiotic strains for humans and companion animals, discovered through the use of their proprietary IVS and IVE platforms, allowing for the isolation of new microbes based on selective and competitive conditions.

Studies

Two-week suplementation

Two-week supplementation of Bifidobacterium adolescentis iVS-1 reduces symptoms associated with lactose intolerance in lactose maldigesters.
Ramakrishnan et al. (2025), Gut Microbes Reports, 2(1).

Complete genome sequence

Complete genome sequence of the probiotic Bifidobacterium adolescentis strain iVS-1.
Chacón-Vargas et al. (2023), Microbiology Resource Announcements, Vol. 12(12).

Galactooligosaccharides

A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults.
Davis et al, 2010

Barcoded Pyrosequencing

Barcoded Pyrosequencing Reveals That Consumption of Galactooligosaccharides Results in a Highly Specific Bifidogenic Response in Humans.
Davis et al, 2011

  • Media
  • References
  • Media
  • References
Contact

health@synbiotichealth.com

Our locations

Discovery & Pre-Clinical Lab
2021 Transformation Drive
Suite 1250 #6
Lincoln, NE 68508

Development, Optimization & Scale-Up
505 Science Drive
Suite C
Madison, WI 53711

  • Privacy Policy
© Synbiotic Health 2025
  • Privacy Policy